Novartis Pelacarsen Lp(a)HORIZON Trial Results: Phase III Study Misses Primary Cardiovascular Endpoint
Novartis announced pelacarsen Lp(a)HORIZON trial results on September 4, 2026, revealing that the Phase III cardiovascular outcomes study did not meet its primary endpoint, even though the investigational therapy lowered Lp(a) levels in more than 8,300 patients with established cardiovascular disease.
